Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

Executive Summary

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

You may also be interested in...



AstraZeneca’s Enthusiasm For Vaccines On The Wane

As an intranasal formulation of Vaxzevria flops in a Phase I study, the attractiveness of investing any more in vaccines R&D could be wearing off for AstraZeneca.

Pfizer’s Talzenna Takes On Top Dog Lynparza In Prostate Cancer

Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.

Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC

A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel